Hydrops lysosomalis generalisatus--an underestimated side effect of hydroxyethyl starch therapy?
Hydroxyethyl starch (HES) is usually considered to be associated with limited side effects. Generalized foamy cell macrophage syndrome after HES therapy has rarely been reported since Schaefer first described it as 'hydrops lysosomalis generalisatus' in 1982. We present a 19-yr-old male who received large amounts of HES. A bone marrow and a liver biopsy were performed because of persistent thrombocytopenia and liver dysfunction. We found severe infiltration of foamy cell degenerated macrophages in both organ systems, indicating that sequelae of HES therapy have to be included in the differential diagnosis of bone marrow and liver dysfunction.
Schmidt-Hieber
Martin
M
Medizinische Klinik III (Hämatologie, Onkologie und Transfusionsmedizin), Charité-Campus Benjamin Franklin, Berlin, Germany. martin.schmidt-hieber@charite.de
Loddenkemper
Christoph
C
Schwartz
Stefan
S
Arntz
Gesine
G
Thiel
Eckhard
E
Notter
Michael
M
D000328:Adult; D001853:Bone Marrow / Q000473:pathology; D004487:Edema / Q000139:chemically induced* / Q000473:pathology; D005487:Foam Cells / Q000473:pathology; D006801:Humans; D006895:Hydroxyethyl Starch Derivatives / Q000009:adverse effects*; D008099:Liver / Q000473:pathology; D008297:Male
D006895:Hydroxyethyl Starch Derivatives